Imago BioSciences Inc
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-03-23
Market Cap:
https://www.imagobio.com
Sec Filling | Patents | 2021 employees
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.
treatment cancer msa t-cell
add to watch list Paper trade email alert is off
ALTERITY THERAPEUTICS LTD
PRNAF
|
$0.0002
-90.0%
11450.0%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-95.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (192.0% volume)
Earnings Calendar:
Market Cap: $ 14,901,366
http://www.pranabio.com
Sec Filling | Patents | n/a employees
(AU) Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
parkinson alzheimer neurodegenerative alzheimer’s
add to watch list Paper trade email alert is off
Sino Biopharmaceutical Limited/ADR
SBMFF
|
$0.3624
64.18%
45K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-33.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (19324.79% volume)
Earnings Calendar:
Market Cap: $ 6,813,561,124
http://www.sinobiopharm.com
Sec Filling | Patents | n/a employees
(HK) Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.
respiratory diabetic diabetes
add to watch list Paper trade email alert is off
Abcam plc
ABCZF
|
$22.1
-2.32%
4K
|
Health Technology
(0.0% 1d) (0.0% 1m) (43.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1011.11% volume)
Earnings Calendar:
Market Cap: $ 5,484,184,018
http://abcam.com
Sec Filling | Patents | n/a employees
(GB) Abcam Plc distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. The company was founded by Adam Robert David Cleevely, Anthony Kouzarides and Jonathan Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.
antibody
add to watch list Paper trade email alert is off
GALAPAGOS NV
GLPGF
|
News
|
$35.5157
71.75%
4.8K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-6.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (240500.0% volume)
Earnings Calendar:
Market Cap: $ 2,274,107,918
http://www.glpg.com
Sec Filling | Patents | n/a employees
(BE) Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
antibody 3d
add to watch list Paper trade email alert is off
MorphoSys AG
MPSYF
|
News
|
$70.28
-71.33%
110
|
Health Technology
(0.0% 1d) (0.0% 1m) (154.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (223918.67% volume)
Earnings Calendar:
Market Cap: $ 2,583,142,384
http://www.morphosys.de
Sec Filling | Patents | n/a employees
(DE) MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
diagnostics antibody
add to watch list Paper trade email alert is off
MESOBLAST LTD
MEOBF
|
$0.1667
314.16%
10K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-72.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (900.0% volume)
Earnings Calendar:
Market Cap: $ 215,452,372
http://www.mesoblast.com
Sec Filling | Patents | n/a employees
(AU) Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
t-cell stem cell ceiling cardiovascular
add to watch list Paper trade email alert is off
Innate Pharma SA
IPHYF
|
$2.65
104.6%
300
|
Health Technology
(0.0% 1d) (13.2% 1m) (-10.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-62.5% volume)
Earnings Calendar:
Market Cap: $ 204,779,375
http://www.innate-pharma.com/en
Sec Filling | Patents | n/a employees
(FR) Innate Pharma SA is a biopharmaceutical company. It focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
cancer immunotherapy antibody t-cell treatment ceiling cancer treatments
add to watch list Paper trade email alert is off
MEDICURE INC
MCUJF
|
$0.7943
0%
13K
|
Health Technology
(0.0% 1d) (4.0% 1m) (-17.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (8500.0% volume)
Earnings Calendar:
Market Cap: $ 8,289,563
http://www.medicure.com
Sec Filling | Patents | n/a employees
(CA) Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. It focuses on the marketing and distribution of its acute care cardiovascular drug, AGGRASTAT; ZYPITAMAG (pitavastatin) tablets and the ReDS device in the United States. The company was founded by Albert D. Friesen on September 15, 1997 and is headquartered in Winnipeg, Canada.
cardiovascular
add to watch list Paper trade email alert is off
Sio Gene Therapies Inc
SIOX
|
$0.478
-20.5%
40K
|
Health Technology
(0.0% 1d) (0.0% 1m) (16.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (84.8% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 35,360,144
http://www.siogtx.com
Sec Filling | Patents | 38 employees
(United Kingdom) Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY.
acquisitions gene therapies parkinson neurological
add to watch list Paper trade email alert is off
Sigilon Therapeutics Inc
SGTX
|
$22.47
-2.56%
0.0%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (172.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (32.61% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 56,500,770
https://sigilon.com
Sec Filling | Patents | 2021 employees
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
diabetic diabetes ceiling t-cell
add to watch list Paper trade email alert is off
Applied Genetic Technologies Corporation
AGTC
|
$0.3936
1.23%
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-80.43% volume)
Earnings Calendar: 2022-11-08
Market Cap:
http://www.agtc.com
Sec Filling | Patents | 83 employees
(US) Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.
gene therapies genetic clinical trials
add to watch list Paper trade email alert is off
Applied Molecular Transport Inc.
AMTI
4
|
$0.263
-14.3%
-1.14%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-16.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.46% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 10,871,516
http://www.appliedmt.com
Sec Filling | Patents | 80 employees
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.
autoimmunity metabolic treatment
add to watch list Paper trade email alert is off
Aptose Biosciences, Inc.
APTO
|
$1.3
-4.41%
-4.62%
62K
|
Health Technology
(0.0% 1d) (-7.2% 1m) (-80.4% 1y) (0.0% 2d) (0.0% 3d) (-4.1% 7d) (425.63% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 20,433,011
http://aptose.com
Sec Filling | Patents | 33 employees
(CA) Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
cancer
add to watch list Paper trade email alert is off
Aravive, Inc.
ARAV
|
$0.0401
4.74%
4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-97.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees
(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.
cancer t-cell ovarian cancer treatment ceiling
add to watch list Paper trade email alert is off
Athersys, Inc.
ATHX
|
$0.1018
-40.86%
95M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-89.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (46.93% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,290,644
http://www.athersys.com
Sec Filling | Patents | 83 employees
(US) Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
cardiovascular stem cell urea t-cell neurological ceiling
add to watch list Paper trade email alert is off
Avadim Health, Inc.
AHI
|
$1.5
0.0%
12K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-76.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-44.79% volume)
Earnings Calendar:
Market Cap: $ 12,933,648
http://www.avadimhealth.com
Sec Filling | Patents | 2 employees
Avadim Health, Inc. operates as a healthcare and wellness company, which sells products to improve immune health, neuromuscular health and skin barrier health. It operates through following segments: Retail Pharmacy/Consumer and Institutional Care. The Retail Pharmacy/Consumer segment primarily includes nationwide pharmacies and other retailers that sell direct to consumers. Institutional Care segment includes acute-care hospitals and nursing homes, as well as other long-term care facilities, including short-term rehabilitation and other facilities designed for post-hospitalization care during recovery. The company was founded by Stephen Woody in 2007 and is headquartered in Asheville, NC.
skin msa
Drugs
CVS (MAGNESIUM SULFATE, UNSPECIFIED FORM)PHUEL (MAGNESIUM SULFATE HEPTAHYDRATE)
Theraworx Patented Foam Formulation (ALLANTOIN)
Theraworx pre-moistened cloths (ALLANTOIN)
Theraworx Relief Joint Discomfort and Inflammation (FRANKINCENSE)
Theraworx Relief Muscle Cramp and Spasm Relief (MAGNESIUM SULFATE HEPTAHYDRATE)
add to watch list Paper trade email alert is off
Avalon GloboCare Corp.
AVCO
|
$0.45
-16.15%
31.11%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-14.4% 3d) (0.0% 7d) (32.38% volume)
Earnings Calendar:
Market Cap:
http://www.avalon-globocare.com
Sec Filling | Patents | 8 employees
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and provision of healthcare services. It operates through the following segments: Real Property Operating; Medical Related Consulting Services; and Development Services and Sales of Developed Products. It offers regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine through Avalon Cell and Avalon Rehab platforms. The company was founded on July 28, 2014 and is headquartered in Freehold, NJ.
immunotherapy t-cell ceiling
add to watch list Paper trade email alert is off
AVEO Pharmaceuticals, Inc.
AVEO
|
$15.0
0.0%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-03-13
Market Cap: $ 521,446,905
http://www.aveooncology.com
Sec Filling | Patents | 19 employees
(US) AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
urea
add to watch list Paper trade email alert is off
Axcella Health Inc.
AXLA
|
$4.58
-56.33%
42K
|
Health Technology
(0.0% 1d) (0.0% 1m) (1032.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1982.28% volume)
Earnings Calendar: 2023-10-31
Market Cap: $ 13,500,512
http://www.axcellahealth.com
Sec Filling | Patents | 64 employees
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.
metabolic
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10